Drug interactions with HMG-CoA reductase inhibitors (statins): The importance of CYP enzymes, transporters and pharmacogenetic

Current Opinion in Investigational Drugs

Volumn 11, Issue 3, 2010, Pages 323-332

  Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cytochrome P450; Drug interaction; HMG CoA reductase inhibitor; Organic anion transporter polypeptide (OATP)1B1 pharmacokinetic; Statin; Transporter protein

Indexed keywords

AMIODARONE; ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; DANAZOL; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; NEFAZODONE; ORGANIC ANION TRANSPORTER 2; PITAVASTATIN; PODOPHYLLOTOXIN; PRAVASTATIN; RIFAMPICIN; RIFAMYCIN; RITONAVIR; ROSUVASTATIN; SIMVASTATIN; TELITHROMYCIN; VERAPAMIL;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG UPTAKE; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MUSCLE DISEASE; MYOPATHY; NONHUMAN; PHARMACOGENETICS; PROTEIN BINDING; REVIEW; RHABDOMYOLYSIS;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS;

EID: 77649135512     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA (2004) 292(21):2585-2590.
2. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ: Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther (2002) 72(6):685-691.
3. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther (2006) 112(1):71-105.
4. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: Mechanism and clinical relevance. Clin Pharmacol Ther (2006) 80(6):565-581.
5. Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K: Effect of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res (2006) 23(3):506-512.
6. Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstøl K: Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther (2006) 79(6):532-539.
7. Skottheim IB, Gedde-Dahl A, Hejazifar S, Hoel K, Asberg A: Statin induced myotoxicity: The lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci (2008) 33(4-5):317-325.
8. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T: Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica (2004) 34(11-12):961-971.
9. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB: Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology (2006) 130(6):1793-1806.
10. Ho RH, Kim RB: Transporters and drug therapy: Implications for drug disposition and disease. Clin Pharmacol Ther (2005) 78(3):260-277.
11. Ayrton A, Morgan P: Role of transport proteins in drug discovery and development: A pharmaceutical perspective. Xenobiotica (2008) 38(7-8):676-708.
12. Hagenbuch B, Gui C: Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica (2008) 38(7-8):778-801.
13. Ieiri I, Higuchi S, Sugiyama Y: Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: Implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol (2009) 5(7):703-729.
14. Kalliokoski A, Niemi M: Impact of OATP transporters on pharmacokinetics. Br J Pharmacol (2009) 158(3):693-705.
15. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos (2005) 33(4):537-546.
16. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/ breast cancer resistance protein. J Pharmacol Exp Ther (2005) 314(3):1059-1067.
17. Kitamura S, Maeda K, Wang Y, Sugiyama Y: Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos (2008) 36(10):2014-2023.
18. Keskitalo JE, Kurkinen KJ, Neuvonen PJ, Niemi M: ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther (2008) 84(4):457-461.
19. Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M: No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Brit J Clin Pharmacol (2009) 68(2):207-213.
20. Kivistö KT, Niemi M, Fromm MF: Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol (2004) 18(6):621-626.
21. Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not of fluvastatin. Clin Pharmacol Ther (2006) 80(4):356-366.
22. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics (2006) 16(12):873-879.
23. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2007) 82(6):726-733.
24. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R: SLCO1B1 variants and statininduced myopathy-A genomewide study. N Engl J Med (2008) 359(8):789-799.
25. Pasanen MK, Neuvonen PJ, Niemi M: Global analysis of genetic variation in SLCO1B1. Pharmacogenomics (2008) 9(1):19-33.
26. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther (2004) 75(5):415-421.
27. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y: Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther (2006) 79(5):427-439.
28. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos (2006) 34(7):1229-1236.
29. Lau YY, Huang Y, Frassetto L, Benet LZ: Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther (2007) 81(2):194-204.
30. He YJ, Zhang W, Chen Y, Guo D, Tu JH, Xu LY, Tan ZR, Chen BL, Li Z, Zhou G, Yu BN et al: Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta (2009) 405(1-2):49-52.
31. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT: Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol (2005) 97(4):249-256.
32. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ: Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther (2000) 68(6):592-597. (Pubitemid 32059984)
33. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ: Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther (2005) 78(2):154-167.
34. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ: Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol (2004) 57(2):181-187.
35. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther (2003) 304(2):610-616.
36. Asberg A: Interactions between cyclosporin and lipidlowering drugs: Implications for organ transplant recipients. Drugs (2003) 63(4):367-378.
37. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW: Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther (2004) 76(2):167-177.
38. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M: Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther (2004) 75(1):101-109.
39. Bergman E, Lundahl A, Fridblom P, Hedeland M, Bondesson U, Knutson L, Lennernas H: Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. Drug Metab Dispos (2009) 37(12):2349-2358.
40. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A: Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab Dispos (2006) 34(1):191-197.
41. Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ: CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: Estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos (2009) 37(12):2359-2366.
42. Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ: Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther (2000) 68(2):122-129. (Pubitemid 30659167)
43. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther (2001) 69(5):340-345.
44. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ: Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther (2003) 73(6): 538-544. (Pubitemid 37249124)
45. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther (2004) 75(5):455-463.
46. Mathew P, Cuddy T, Tracewell WG, Salazar D: An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin Pharmacol Ther (2004) 75(2):P33.
47. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE: Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol (1995) 76(2):80A-83A.
48. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF et al: Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta (2006) 373(1-2):99-103.
49. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M: ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2009) 86(2):197-203.
50. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M: Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics (2009) 10(10):1617-1624.
51. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S et al: SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther (2007) 82(5):541-547.
52. Jones HM, Parrott N, Jorga K, Lavé T: A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet (2006) 45(5):511-542.
53. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y: Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther (2009) 328(2):652-662.
54. Neuvonen PJ, Jalava KM: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther (1996) 60(1):54-61.
55. Neuvonen PJ, Kantola T, Kivistö KT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther (1998) 63(3):332-341.
56. Kantola T, Kivistö KT, Neuvonen PJ: Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther (1998) 64(1):58-65.
57. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV: Effect of itraconazole on the pharmacokinetics rosuvastatin. Clin Pharmacol Ther (2003)73(4):322-329.
58. Kivistö KT, Kantola T, Neuvonen PJ: Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol (1998) 46(1):49-53.
59. Kantola T, Kivistö KT, Neuvonen PJ: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther (1998) 64(2):177-182.
60. Lilja JJ, Kivistö KT, Neuvonen PJ: Grapefruit-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid and HMG-CoA reductase inhibitors. Clin Pharmacol Ther (1998)64(5):477-483.
61. Lilja JJ, Neuvonen M, Neuvonen PJ: Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol (2004)58(1):56-60.
62. Kantola T, Kivistö KT, Neuvonen PJ: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther (1998)63(4):397-402.
63. Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ: Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol (2000)56(3):225-229.
64. Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, Zanger UM: UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther (2010) 87(1):64-73.
65. Zhang W, Deng S, Chen XP, Zhou G, Xie HT, He FY, Cao D, Li YJ, Zhou HH: Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: A randomized, single-blind, placebo-controlled, crossover study. Clin Ther (2008) 30(7):1283-1289.